Oncologica Prostatefocus Genetic Screening Test

Oncologica, a Cambridge, UK-based genetic cancer and viral testing laboratory, has launched its Prostatefocus cancer genetic screening test intended to identify men at increased risk of developing prostate cancer. The test analyzes DNA damage-repair genes using a saliva sample provided by the patient via a self-sample collection kit or collected in clinic. The test is sent to Oncologica's UKAS-accredited laboratory for genomic analysis, and results are available within seven days of receipt. A healthcare partner then arranges a post-test follow up with the test subject, the company said. The test is currently commercially available in the UK, Ireland, and Italy, a company spokesperson said.